The tyrosine kinase (TK) inhibitor imatinib provides a highly effective therapy for chronic myeloid leukemia (CML) via inhibition of the oncogenic TK BCR-ABL1. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.